Twist Bioscience
TWST Mid CapHealthcare · Diagnostics & Research
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Twist Bioscience en bref
Twist Bioscience (TWST) is currently trading at 79,37 € with a market capitalization of 4,9 Md €. The 52-week range spans from 20,20 € to 91,44 €; the current price is 13.2% below the yearly high. Year-over-year revenue growth stands at +19.3%.
💰 Dividende
Twist Bioscience currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
10 analystes évaluent Twist Bioscience (TWST) au consensus : Acheter. L'objectif de cours moyen est de 80,20 €, soit un potentiel de +1.04% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 31,21 € à 104,04 €.
Twist Bioscience : la thèse d'investissement en détail
Twist Bioscience (TWST) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 19.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 2.12, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 29.08% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 52.07% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 24.36)
- –Actuellement non rentable
- –Forte volatilité (Bêta 2.12)
- –Positions vendeuses élevées (29.08%)
- –Free cash flow négatif
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to above-average price swings, elevated short interest (29.08%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Twist Bioscience?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
